<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Rheumatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin. Rheumatol</journal-id>
      <journal-title-group>
        <journal-title>Clinical Rheumatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0770-3198</issn>
      <issn pub-type="epub">1434-9949</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20379839</article-id>
      <article-id pub-id-type="pmc">3594820</article-id>
      <article-id pub-id-type="publisher-id">1438</article-id>
      <article-id pub-id-type="doi">10.1007/s10067-010-1438-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kuwabara</surname>
            <given-names>Hiroko</given-names>
          </name>
          <address>
            <email>pa2020@art.osaka-med.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukuda</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsuda</surname>
            <given-names>Yasuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shibayama</surname>
            <given-names>Yuro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Pathology, Osaka Medical College, 2-7, Daigaku-machi, Takatsuki, Osaka 569-8686 Japan </aff>
        <aff id="Aff2"><label/>Department of Internal Medicine, Osaka Medical College, 2-7, Daigaku-machi, Takatsuki, Osaka 569-8686 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>4</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>4</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>32</volume>
      <issue>Suppl 1</issue>
      <fpage>47</fpage>
      <lpage>49</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>2</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>3</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2010</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>A 73-year-old female, who suffered from rheumatoid arthritis for 10&#xA0;years, developed precore mutant hepatitis B virus-associated fulminant hepatitis after 1&#xA0;year of infliximab therapy and subsequent methotrexate withdrawal. We emphasize the importance of preemptive antiviral therapy before starting infliximab administration and withdrawing immunosuppressive drugs.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Fulminant hepatitis</kwd>
        <kwd>HBV</kwd>
        <kwd>Infliximab</kwd>
        <kwd>MTX</kwd>
        <kwd>Rheumatoid arthritis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Clinical Rheumatology 2013</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Infliximab, a tumor necrosis factor-&#x3B1; (TNF-&#x3B1;) inhibitor, has become the standard therapy for active rheumatoid arthritis (RA), but also has influences on bacterial, viral, and tuberculous infections [<xref ref-type="bibr" rid="CR1">1</xref>]. In particular, the reactivation of hepatitis B virus (HBV) is problematic [<xref ref-type="bibr" rid="CR2">2</xref>] and HBV-induced fulminant hepatitis following infliximab treatment has been reported in patients with Crohn&#x2019;s disease and Still&#x2019;s disease [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. Here, we describe an autopsy case of RA who developed precore mutant HBV-associated fulminant hepatitis after 1&#xA0;year of infliximab therapy and subsequent methotrexate (MTX) withdrawal.</p>
    </sec>
    <sec id="Sec2">
      <title>Case report</title>
      <p>A 73-year-old female, with a 10-year history of RA, had been treated with prednisone (5&#x2013;10&#xA0;mg/day) and MTX (5&#x2013;8&#xA0;mg/week) for 10 and 6&#xA0;years, respectively. These were ineffective, and infliximab (150&#xA0;mg every 8&#xA0;weeks, 3&#xA0;mg/kg) was added between June 2004 and May 2005, with liver function tests at each infusion. A pretreatment screening test showed that HBsAg and HBcAb were positive, and hepatitis C virus antibody was negative. Liver tests and images showed no abnormalities. MTX and prednisone were tapered, and prednisone was withdrawn in April 2005. An effective clinical improvement of joint disease was observed, and C reactive protein became normal. After the eighth infusion of infliximab, the liver function was found to be abnormal (AST 291&#xA0;IU/L (normal &lt;40), ALT 331&#xA0;IU/L (&lt;40)), and MTX therapy was withdrawn. Her liver function progressively worsened (AST 1690&#xA0;IU/L, ALT 1390&#xA0;IU/L), and she was admitted to our hospital in June 2005.</p>
      <p>On admission, she had jaundice and mild hepatic encephalopathy. Laboratory data revealed AST 393&#xA0;IU/L, ALT 544&#xA0;IU/L, &#x3B3;GTP 130&#xA0;IU/L (&lt;30), LDH 364&#xA0;IU/L (115&#x2009;&#x223C;&#x2009;245), total bilirubin 15.7&#xA0;mg/dL (&lt;1.0), prothrombin time 8% (&gt;70), and NH<sub>3</sub> 168&#xA0;&#xB5;g/dL (30&#x2009;&#x223C;&#x2009;80). Her serological status was as follows: HBsAg, HBeAb, and IgM HBcAb were positive, while HBsAb and HBeAg were negative. HBV-DNA was present with a level of 4.3 log copies per milliliter (&lt;2.6) by polymerase chain reaction assay. HBV was of genotype B and the precore mutant was 100%. She had no HIV and IgM hepatitis A virus antibodies. An abdominal computed tomography (CT) scan showed atrophic liver. Therefore, a diagnosis of fulminant hepatitis due to the reactivation of HBV from a previously asymptomatic HBV carrier state was made, and lamivudine (a reverse-transcriptase inhibitor of viral DNA polymerase) therapy (150&#xA0;mg/day) and plasma exchange were immediately performed. Her condition temporarily improved, and liver transplantation was considered. However, her liver function deteriorated and an abdominal CT showed more atrophic liver. She died of liver failure 18&#xA0;days after admission. A postmortem examination was performed, and the ascites volume was 170&#xA0;mL. The liver was remarkably atrophied, weighing just 508&#xA0;g, and more than 80% of the hepatocytes were necrotic. CD8-positive cytotoxic T lymphocytes had predominantly infiltrated, and amyloid A protein deposition as a result of RA was seen in the hepatic artery (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Vessels in most organs showed amyloid A protein deposition.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Liver histology. <bold>a</bold> Massive hepatocytic necrosis (H&amp;E stain, 4&#xD7;). <bold>b</bold> Predominantly infiltrated CD8 positive lymphocytes (20&#xD7;). <bold>c</bold> Amyloid A immunoreactivity of the hepatic artery (10&#xD7;)</p></caption><graphic xlink:href="10067_2010_1438_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>Our case suggests that infliximab treatment induces HBV precore mutation and the destruction of HBV-infected hepatocytes by CD8-positive cytotoxic T lymphocytes. The HBV precore mutation is involved in the pathogenesis of fulminant hepatitis [<xref ref-type="bibr" rid="CR7">7</xref>], and the reactivation of a precore mutant HBV during infliximab therapy has been reported [<xref ref-type="bibr" rid="CR8">8</xref>]. TNF-&#x3B1; has antiviral properties by inhibiting the replication of HBV DNA and mediates apoptosis of cytotoxic T lymphocytes [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. TNF-&#x3B1; inhibitors may induce fulminant hepatitis following the reactivation of precore mutant HBV and the proliferation of cytotoxic T lymphocytes. In addition to infliximab, long-term MTX treatment and subsequent withdrawal may accelerate HBV reactivation. HBV-positive patients are at increased risk of fulminant hepatic failure after withdrawing immunosuppressive drugs such as MTX because of the hepatocytic attack following sudden reaction of the immune system [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>Preemptive antiviral therapy with lamivudine is recommended as part of infliximab therapy for HBV-positive patients, even if they have normal liver function or an undetectable viral load [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The delayed onset of antiviral therapy in our patient may have been responsible for the fatal outcome. This case shows that infliximab therapy in an HBV-positive patient with RA can lead to fulminant hepatitis, possibly through the reactivation of precore mutant HBV and the proliferation of cytotoxic T lymphocytes. In addition, this case illustrates the importance of anti-HBV therapy before starting infliximab administration and withdrawing immunosuppressive drugs.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec id="d29e282">
        <title>Disclosures</title>
        <p>None</p>
      </sec>
      <sec id="d29e287">
        <title>Open Access</title>
        <p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furst</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Keystone</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Breedveld</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009</article-title>
          <source>Ann Rheum Dis</source>
          <year>2010</year>
          <volume>69</volume>
          <issue>Suppl 1</issue>
          <fpage>i2</fpage>
          <lpage>i29</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2009.123885</pub-id>
          <pub-id pub-id-type="pmid">19995740</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostuni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Botsios</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Punzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sfriso</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Todesco</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate</article-title>
          <source>Ann Rheum Dis</source>
          <year>2003</year>
          <volume>62</volume>
          <fpage>686</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.62.7.686</pub-id>
          <pub-id pub-id-type="pmid">12810441</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esteve</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saro</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gonzalez-Huix</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Suarez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Forne</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Viver</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Chronic hepatitis B reactivation following infliximab therapy in Crohn&#x2019;s disease patients: need for primary prophylaxis</article-title>
          <source>Gut</source>
          <year>2004</year>
          <volume>53</volume>
          <fpage>1363</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.2004.040675</pub-id>
          <pub-id pub-id-type="pmid">15306601</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Millonig</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ludwiczek</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Nachbaur</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Subfulminat hepatitis B after infliximab in Crohn&#x2019;s disease: need for HBV-screening?</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>974</fpage>
          <lpage>976</lpage>
          <pub-id pub-id-type="pmid">16521231</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colbert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chavarria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Berkelhammer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn&#x2019;s disease</article-title>
          <source>Inflamm Bowel Dis</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>1453</fpage>
          <lpage>1454</lpage>
          <pub-id pub-id-type="doi">10.1002/ibd.20216</pub-id>
          <pub-id pub-id-type="pmid">17600380</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Duvoux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hezode</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cherqui</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still&#x2019;s disease</article-title>
          <source>J Rheumatol</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>1624</fpage>
          <lpage>1625</lpage>
          <pub-id pub-id-type="pmid">12858469</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>WN</given-names>
            </name>
            <name>
              <surname>Oon</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Human hepatitis B virus mutants: significance of molecular changes</article-title>
          <source>FEBS Lett</source>
          <year>1999</year>
          <volume>453</volume>
          <fpage>237</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-5793(99)00704-8</pub-id>
          <pub-id pub-id-type="pmid">10405152</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wendling</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Auge</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bettinger</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lohse</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huede</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Bresson-Hadni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Toussirot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Miguet</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Herbein</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martino</surname>
              <given-names>VD</given-names>
            </name>
          </person-group>
          <article-title>Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>788</fpage>
          <lpage>789</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.031187</pub-id>
          <pub-id pub-id-type="pmid">15834064</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlaak</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Tully</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lohr</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Gerken</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Buschenfelde</surname>
              <given-names>KH</given-names>
            </name>
          </person-group>
          <article-title>HBV-specific immune defect in chronic hepatitis B is correlated with a dysregulation of pro- and anti-inflammatory cytokines</article-title>
          <source>Clin Exp Immunol</source>
          <year>1999</year>
          <volume>115</volume>
          <fpage>508</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2249.1999.00812.x</pub-id>
          <pub-id pub-id-type="pmid">10193426</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Moriyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Guidotti</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Wirth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Schlicht</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chisari</surname>
              <given-names>FV</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis</article-title>
          <source>J Exp Med</source>
          <year>1993</year>
          <volume>178</volume>
          <fpage>1541</fpage>
          <lpage>1554</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.178.5.1541</pub-id>
          <pub-id pub-id-type="pmid">8228807</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakazono</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Murasawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gejyo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient</article-title>
          <source>Arthritis Rheum</source>
          <year>2001</year>
          <volume>44</volume>
          <fpage>339</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.1002/1529-0131(200102)44:2&lt;339::AID-ANR51&gt;3.0.CO;2-Q</pub-id>
          <pub-id pub-id-type="pmid">11229464</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>YB</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-&#x3B1; therapy</article-title>
          <source>J Rheumatol</source>
          <year>2009</year>
          <volume>36</volume>
          <fpage>2416</fpage>
          <lpage>2420</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.081324</pub-id>
          <pub-id pub-id-type="pmid">19797507</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
